Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

721 recalls, newest first

Class II · Moderate risk

Ciprofloxacin Ophthalmic Solution USP

Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect FDC Limited NDC 69315-308-05 D-0282-2025
Class II · Moderate risk

Duloxetine D/R

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Ongoing Nitrosamine impurity Direct Rx NDC 61919-0482-30 D-0568-2025
Class II · Moderate risk

Duloxetine D/R

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Ongoing Nitrosamine impurity Direct Rx NDC 61919-422-30 D-0567-2025
Class II · Moderate risk

Prasugrel Tablets

Failed Dissolution Specifications

Ongoing Dissolution failure Golden State Medical Supply Inc. NDC 51407-444-30 D-0287-2025
Class II · Moderate risk

Unisom

CGMP Deviations: Nitrosamine Drug Substance Related Issue impurity above the daily acceptable intake limit defined by the Food and Drug Administration.

Ongoing Nitrosamine impurity Chattem Inc D-0266-2025
Class II · Moderate risk

Carvedilol Tablets USP 25 mg

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-165-05 D-0451-2025
Class II · Moderate risk

Carvedilol Tablets USP 12.5 mg

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA D-0450-2025
Class II · Moderate risk

Carvedilol Tablets USP 6.25 mg

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-163-01 D-0449-2025

Recalls by year